GlassScriptPhysician profile
Rabiya Suleman
NPI 1750572566
$3,932.53
in general payments reported to CMS, 2019-2025
33 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $284 · 2021: $691 · 2022: $1,272 · 2023: $600 · 2024: $475 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.99 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gynesonics, INC. | $675.46 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Abbvie INC. | $651.88 | 2019-2024 | Lo Loestrin Fe |
| Organon LLC | $261.53 | 2021-2025 | Nexplanon, Jada System |
| Sumitomo Pharma America, INC. | $211.97 | 2023-2025 | Myfembree |
| Merck Sharp & Dohme LLC | $172.05 | 2019-2021 | |
| Astellas Pharma US INC | $166.45 | 2023-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $154.76 | 2021-2023 | Truclear |
| Biogen, INC. | $150.87 | 2024-2025 | Zurzuvae |
| Applied Medical Resources Corporation | $136.24 | 2022 | |
| Myovant Sciences INC. | $120.76 | 2021-2022 | |
| Agile Therapeutics, INC. | $108.04 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $103.95 | 2019-2025 | |
| Novo Nordisk INC | $96.96 | 2019-2025 | Wegovy |
| Therapeuticsmd, INC. | $89.68 | 2020-2021 | |
| Lilly USA, LLC | $89.00 | 2023-2024 | Zepbound, Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $83.76 | 2020-2025 | Paragard T 380a |
| Mayne Pharma Commercial LLC | $81.54 | 2021-2024 | |
| Exeltis, USA INC. | $79.69 | 2021-2023 | Slynd |
| Ascend Therapeutics US, LLC | $57.48 | 2022-2023 | |
| Hologic Sales and Service, LLC | $52.46 | 2019-2025 | Thinprep 2000 Processor, Aptima, Third Wave |
| Millicent US INC | $49.90 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Mylan Pharmaceuticals INC. | $41.70 | 2021 | |
| Pfizer INC. | $39.91 | 2023-2024 | |
| Allergan, INC. | $39.89 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.53 | 2019-2022 | |
| Olympus America INC. | $36.28 | 2019 | |
| Genzyme Corporation | $32.60 | 2024 | |
| Minerva Surgical, INC | $26.82 | 2022 | |
| Axonics, INC. | $18.05 | 2021 | |
| Dexcom, INC. | $17.25 | 2024 | Dexcom G6 Transmitter |
| Covidien LP | $16.81 | 2019 | |
| Ibsa Pharma INC. | $16.22 | 2023 | Tirosint, Licart |
| Boston Scientific Corporation | $13.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabiya Suleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.